Latest Amyloid precursor protein secretase Stories

Researchers pinpoint a small RNA that spurs cells to manufacture a particular splice variant of a key neuronal protein, potentially promoting Alzheimer's disease (AD) or other types of neurodegeneration. The study appears in the May 30 issue of The Journal of Cell Biology (www.jcb.org).Like a movie with an alternate ending, a protein can come in more than one version. Although scientists have identified numerous proteins and RNAs that influence alternative splicing, they haven't deciphered...

(Ivanhoe Newswire) "“ Researchers pinpoint a small RNA that triggers cells to manufacture a particular splice variant of a key neuronal protein, potentially promoting Alzheimer's disease (AD) or other types of neurodegeneration.Like a movie with an alternate ending, a protein can come in more than one version. Although scientists have identified numerous proteins and RNAs that influence alternative splicing, they haven't deciphered how cells fine-tune the process to produce specific protein...

A drug used to treat asthma has been shown to help reduce the formation of amyloid beta, a peptide in the brain that is implicated in the development of Alzheimer's disease, according to researchers at Temple University's School of Medicine.The researchers published their findings, "Pharmacologic Blockade of 5-Lipoxygenase Improves the Amyloidotic Phenotype of an AD Transgenic Mouse Model," in the American Journal of Pathology.In previous studies, the Temple researchers discovered...

Mount Sinai School of Medicine researchers have found that a gene associated with the onset of Type 2 diabetes also is found at lower-than-normal levels in people with Alzheimer's disease. The research, led by Giulio Maria Pasinetti, MD, PhD, The Saunder Family Professor in Neurology, and Professor of Psychiatry and Geriatrics and Adult Development at Mount Sinai School of Medicine, was published this month in Aging Cell.The new study provides insight into a potential mechanism that might...

NEW YORK, Sept. 1 /PRNewswire-USNewswire/ -- Researchers at the Fisher Center for Alzheimer's Disease Research laboratory today published "Gamma-secretase Activating Protein is a Therapeutic Target for Alzheimer's Disease" in Nature online. Drs. Gen He (lead author) and Paul Greengard have discovered a protein that stimulates the production of beta-amyloid, and therefore represents a major new advance in Alzheimer's disease research. The protein, called gamma-secretase activating protein...

HONOLULU, July 14 /PRNewswire/ -- EnVivo Pharmaceuticals today announced at the Alzheimer's Association 2010 International Conference on Alzheimer's Disease (ICAD) results from its proprietary gamma-secretase modulator (GSM) pre-clinical study. In a transgenic mouse model, EnVivo's EVP-0015962 reduced amyloid plaque buildup which is believed to be a cause of Alzheimer's disease, reversed behavioral deficits and reduced brain inflammation associated with Alzheimer's disease. EVP-0015962 is...

Reducing a protein called beta-amyloid in young mice with a condition resembling Down syndrome improves their ability to learn, researchers at UT Southwestern Medical Center have found."This preliminary study in the animal model raises the intriguing possibility that drugs that lower beta-amyloid levels might offer some benefit to children with Down syndrome," said Dr. Craig Powell, assistant professor of neurology at UT Southwestern and co-lead author of the study, which is...

WATERTOWN, Mass., Dec. 8 /PRNewswire/ -- EnVivo Pharmaceuticals today reported the successful reduction in the levels of aggregated Abeta or Beta-Amyloid in an aged transgenic model (Tg2576) of Alzheimer's disease with its lead gamma-secretase modulator (GSM) EVP-0962. The aggregated Abeta, containing predominately oligomeric and larger Abeta fibrillar species, is considered to be the toxic entity in Alzheimer's disease. The reduction of these aggregates further supports the disease...

VIENNA, July 14 /PRNewswire/ -- EnVivo Pharmaceuticals today announced at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD) the reversal of behavioral deficits observed in an Alzheimer's disease transgenic animal model after chronic oral dosing of a proprietary gamma-secretase modulator (GSM). The data was disclosed as part of the preclinical characterization of the development candidate EVP-0962. EVP-0962 is a proprietary small molecule that belongs...

They say the findings cement relationship between the two brain disordersThe destructive cellular pathways activated in Alzheimer's disease are also triggered following traumatic brain injury, say researchers from Georgetown University Medical Center (GUMC). They say this finding suggests that novel therapy might successfully target both conditions.In an oral presentation at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease, the scientists will show that...